Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for VistaGen Therapeutics, Inc. (VTGN : NSDQ)
 
 • Company Description   
VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.

Number of Employees: 57

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.00 Daily Weekly Monthly
20 Day Moving Average: 187,024 shares
Shares Outstanding: 29.16 (millions)
Market Capitalization: $58.31 (millions)
Beta: 0.61
52 Week High: $4.21
52 Week Low: $1.90
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -15.25% -19.02%
12 Week -5.66% -19.42%
Year To Date -32.20% -36.50%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
343 ALLERTON AVENUE
-
SOUTH SAN FRANCISCO,CA 94080
USA
ph: 650-577-3600
fax: 888-482-2602
markmcp@vistagen.com http://www.vistagen.com
 
 • General Corporate Information   
Officers
Shawn K. Singh - Chief Executive Officer; and Director
Margaret M. FitzPatrick - Chairman
Cynthia L. Anderson - Chief Financial Officer and Treasurer
Ann M. Cunningham - Director
Joanne Curley - Director

Peer Information
VistaGen Therapeutics, Inc. (CORR.)
VistaGen Therapeutics, Inc. (RSPI)
VistaGen Therapeutics, Inc. (CGXP)
VistaGen Therapeutics, Inc. (BGEN)
VistaGen Therapeutics, Inc. (GTBP)
VistaGen Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 92840H400
SIC: 2834
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
Share - Related Items
Shares Outstanding: 29.16
Most Recent Split Date: 6.00 (0.03:1)
Beta: 0.61
Market Capitalization: $58.31 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.54 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.80 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.82
Price/Cash Flow: -
Price / Sales: 83.55
EPS Growth
vs. Year Ago Period: -72.00%
vs. Previous Quarter: 6.52%
Sales Growth
vs. Year Ago Period: -43.07%
vs. Previous Quarter: 27.87%
ROE
06/30/25 - -
03/31/25 - -58.88
12/31/24 - -48.12
ROA
06/30/25 - -
03/31/25 - -52.38
12/31/24 - -43.80
Current Ratio
06/30/25 - -
03/31/25 - 6.51
12/31/24 - 9.35
Quick Ratio
06/30/25 - -
03/31/25 - 6.51
12/31/24 - 9.35
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -6,777.08
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -6,777.08
Pre-Tax Margin
06/30/25 - -
03/31/25 - -10,578.40
12/31/24 - -6,775.93
Book Value
06/30/25 - -
03/31/25 - 2.44
12/31/24 - 2.91
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©